sacubitril and valsartan (Entresto®)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II to IV) and reduced ejection fraction; usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme (ACE) inhibitor or other angiotensin II receptor blocker (ARB)

Patients must meet the following criteria for the indications above:

  • Chronic Heart Failure (NYHA class II to IV) and reduced ejection fraction
  • Diagnosis of CHF NYHA class II to IV AND
  • Patient is being followed by (care coordinated by) a cardiologist

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All non-FDA approved uses not listed in the approved indications

Dosing:

Adult Usual dosage

  • Sacubitril 97 mg/valsartan 103 mg twice daily
  • Initial dosage:   Patients previously taking greater than enalapril 10 mg/day or greater than valsartan 160 mg/day or equivalent dose of another ACE inhibitor or ARB: Sacubitril 49 mg/valsartan 51 mg twice daily
  • Patients previously taking low doses of an ACE inhibitor (enalapril 10 mg/day or less or an equivalent dose of another ACE inhibitor) or ARB (valsartan 160 mg/day or less or an equivalent dose of another ARB): Sacubitril 24 mg/valsartan 26 mg twice daily
  • Patients not currently taking an ACE inhibitor or an ARB: Sacubitril 24 mg/valsartan 26 mg twice daily
  • Dosage titration: Double the dose as tolerated every 2 to 4 weeks to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg twice daily
  • Concomitant therapy: Concomitant use of an ACE inhibitor is contraindicated; allow a 36-hour washout period when switching from or to an ACE inhibitor

Pediatric

  • Safety and efficacy have not been established

Renal function impairment

  • Estimated glomerular filtration rate 30 mL/min/1.73 m2 or more: No dosage adjustment necessary
  • Estimated glomerular filtration rate less than 30 mL/min/1.73 m2: Initiate with sacubitril 24 mg/valsartan 26 mg twice daily

Hepatic function impairment

  • Mild impairment (Child-Pugh class A): No dosage adjustment necessary
  • Moderate impairment (Child-Pugh class B): Initiate with sacubitril 24 mg/valsartan 26 mg twice daily

Approval:

One year


  

Last review date: July 24, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar